ConductScience.org, home

Paper39347697

Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.

Shah SJ and 11 others. JAMA Cardiol, 2025. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial. Papers, record 39347697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39347697

Download JSON
Disease
heart failure311 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.
PubMed
Journal
JAMA Cardiol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase II, Multicenter Study
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
8.8, provisional
iCite
Revised in PubMed
2026-09-10
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shah SJSanjiv J
2Rigolli MMarzia
3Javidialsaadi AAtefeh
4Patel RBRavi B
5Khadra SSuhail
6Goyal PParag
7Little SSean
8Wever-Pinzon OOmar
9Owens ATAnjali Tiku
10Skali HHicham
11Arora PPankaj
12Solomon SDScott D

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiac MyosinsMajor topic
Heart FailureMajor topic
Stroke VolumeMajor topic
UracilMajor topic
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Echocardiography
Natriuretic Peptide, Brain
Peptide Fragments
Treatment Outcome
Ventricular Function, Left
Proof of Concept Study
Benzylamines

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
U54HL160273NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04766892A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121440868Decreased cardiac functional reserve in heart failure with preserved systolic function.J Card Fail2011https://conductscience.org/library/papers/21440868PubMed
231386109Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?Eur Heart J2020https://conductscience.org/library/papers/31386109PubMed
336994635Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction.Eur J Heart Fail2023https://conductscience.org/library/papers/36994635PubMed
436029466DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure.Circulation2022https://conductscience.org/library/papers/36029466PubMed
532871100Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2020https://conductscience.org/library/papers/32871100PubMed
616487838B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.J Am Coll Cardiol2006https://conductscience.org/library/papers/16487838PubMed
735502770Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter.J Am Heart Assoc2022https://conductscience.org/library/papers/35502770PubMed
837804245Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.Eur Heart J2023https://conductscience.org/library/papers/37804245PubMed
935862208Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction.Circulation2022https://conductscience.org/library/papers/35862208PubMed
1033750209Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.Circulation2021https://conductscience.org/library/papers/33750209PubMed
1117707182Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.J Am Coll Cardiol2007https://conductscience.org/library/papers/17707182PubMed
1237191180Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study.Eur J Heart Fail2023https://conductscience.org/library/papers/37191180PubMed
1332466879Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.J Am Coll Cardiol2020https://conductscience.org/library/papers/32466879PubMed
1424184245Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.J Am Coll Cardiol2014https://conductscience.org/library/papers/24184245PubMed
1535435607The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.Am J Cardiovasc Drugs2022https://conductscience.org/library/papers/35435607PubMed

Download CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
42814187Complication management in hypertrophic cardiomyopathy.Heart Fail Rev2026https://conductscience.org/library/papers/42814187PubMed
42781371Coronary microvascular dysfunction in HFpEF: pathophysiologic mechanisms, diagnosis, treatments, and the amplifying potential of sepsis.Front Med (Lausanne)2026https://conductscience.org/library/papers/42781371PubMed
42762037Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.Arch Intern Med Res2026https://conductscience.org/library/papers/42762037PubMed
42591999Mitochondrial-inflammatory coupling in HFpEF: an emerging mechanistic framework for understanding the cardioprotective effects of SGLT2 inhibitors.Front Cardiovasc Med2026https://conductscience.org/library/papers/42591999PubMed
42362932Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium.Basic Res Cardiol2026https://conductscience.org/library/papers/42362932PubMed
42182770Heart failure in 2025: new insights, therapies, and clinical directions.J Thorac Dis2026https://conductscience.org/library/papers/42182770PubMed
42024776Severe obesity in human HFpEF alters contractile protein function and organization.Science2026https://conductscience.org/library/papers/42024776PubMed
41659088Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy.Rev Cardiovasc Med2026https://conductscience.org/library/papers/41659088PubMed
41528064Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.Eur Heart J2026https://conductscience.org/library/papers/41528064PubMed
41497974NEW TREATMENTS FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION.Ulster Med J2025https://conductscience.org/library/papers/41497974PubMed
41324783Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data.Curr Cardiol Rep2025https://conductscience.org/library/papers/41324783PubMed
41127363Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects.Drug Des Devel Ther2025https://conductscience.org/library/papers/41127363PubMed
40977229Deep phenotyping of heart failure with preserved ejection fraction through multi-omics integration.Eur J Heart Fail2025https://conductscience.org/library/papers/40977229PubMed
40890312Beta blockers linked to reduced 1-Year mortality in critically ill congestive heart failure patients with differential benefits across subgroups.Sci Rep2025https://conductscience.org/library/papers/40890312PubMed
40869375Novel Drug Targets in Diastolic Heart Disease.Int J Mol Sci2025https://conductscience.org/library/papers/40869375PubMed
40867543Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges.Biomolecules2025https://conductscience.org/library/papers/40867543PubMed
40807027Current Treatment of Heart Failure with Preserved Ejection Fraction.J Clin Med2025https://conductscience.org/library/papers/40807027PubMed
40722692Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy.Biomedicines2025https://conductscience.org/library/papers/40722692PubMed
40624601Cardiac myosin inhibitors in hypertrophic cardiomyopathy.J Cardiovasc Imaging2025https://conductscience.org/library/papers/40624601PubMed
40584916Pathophysiological and prognostic relevance of exercise CMR-derived pulmonary artery compliance in patients with suspected diastolic dysfunction and normal right ventricular function.Eur Heart J Imaging Methods Pract2025https://conductscience.org/library/papers/40584916PubMed

See all 26 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
MAVACAMTENCHEMBL4297517Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297517

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39347697

GET https://conductscience.org/api/papers/v1/39347697/cited_by?page=2